Ohio University
Athens, Ohio, 45701, United States
NCT Number: NCT03056417
The current project will use the Complete Health Improvement Program (CHIP) as an intervention for patients with chronic pain. CHIP is a nationally recognized program that encourages a diet of whole plant-based foods, moderate exercise, stress reduction, and social support. Patients with chronic pain who enroll in CHIP classes will be monitored and compared to patients with chronic pain who are not enrolled in CHIP classes. It is hypothesized that patients who complete CHIP will have increased telomerase activity and longer relative telomere length at follow-up when compared to those who do not enroll in the program. Chromosomes consist of DNA that contains the genetic makeup of an individual; and telomeres are the caps on these chromosomes that protect them from damage. Telomere shortening occurs normally with aging and once they are too short to replicate cellular death occurs. Telomerase is a ribonucleic protein that counterbalances this shortening by extending the ends of chromosomes. Research has shown that patients with chronic pain may have shorter telomeres relative to others of the same age. This study will investigate this association further.
Looking for future studies?
Notify Me40 year–70 year
All sexes
Interventional
Not applicable
Athens, Ohio, 45701, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The Complete Health Improvement Program is a nationally recognized program that encourages a diet of whole plant based foods, moderate exercise, stress reduction, and social support.
Time frame: Change from baseline telomerase at 3 months
Assessed via peripheral blood mononuclear cells
Time frame: Change from baseline subjective pain at 3 months
Assessed via the Brief Pain Inventory - Short Form. Measures pain intensity from 0 to 10, 10 being pain as bad as you can imagine. Also measures the extent to which pain interferes with daily functioning (0 - 10 possible, with 10 indicating completely interferes).
Time frame: Change from baseline telomere length at 3 months
Assessed via whole blood samples
Time frame: Change from 3 month follow-up data of telomere length at 1-year
Assessed via whole blood samples
Time frame: Change from baseline fasting glucose at 3 months
Assessed via whole blood samples
Time frame: Change from 3 month follow-up data of fasting glucose at 1-year
Assessed via whole blood samples
Time frame: change from baseline fasting lipids at 3 months
Assessed via whole blood
Time frame: Change from 3 month follow-up data of fasting lipids at 1-year
Assessed via whole blood
Time frame: change from baseline C-reactive protein at 3 months
Assessed via plasma
Time frame: Change from 3 month follow-up data of C-reactive protein at 1-year
Assessed via plasma
Time frame: change from baseline overall well-being at 3 months
The RAND-36 item short form survey. High score indicates more favorable health state. Minimum score 0 Maximum score 100.
Time frame: Change from 3 month follow-up data of overall well-being at 1-year
The RAND-36 item short form survey. High score indicates more favorable health state. Minimum score 0 Maximum score 100.
Time frame: change from baseline perceived stress at 3 months
The 14-item Perceived Stress Scale. Minimum score 0 Maximum score 40. Higher scores indicate greater perceived stress.
Time frame: Change from 3 month follow-up data of perceived stress at 1-year
The 14-item Perceived Stress Scale. Minimum score 0 Maximum score 40. Higher scores indicate greater perceived stress.
Time frame: change from baseline depressed mood at 3 months
Center for Epidemiological Studies Depression Scale. Higher score indicates greater depressed mood. Minimum score 0 Maximum score 60.
Time frame: Change from 3 month follow-up data of depressed mood at 1-year
Center for Epidemiological Studies Depression Scale. Higher score indicates greater depressed mood. Minimum score 0 Maximum score 60.
Time frame: change from baseline perceived social support at 3 months
Multidimensional Scale of Perceived Social Support. Higher score indicates greater perceived social support. Minimum score 1 Maximum score 7.
Time frame: Change from 3 month follow-up data of perceived social support at 1-year
Multidimensional Scale of Perceived Social Support. Higher score indicates greater perceived social support. Minimum score 1 Maximum score 7.
Time frame: change from baseline health promoting behavior at 3 months
Health-Promoting Lifestyle Profile II questionnaire. Higher score indicate greater health promotion. Minimum score 1 Maximum score 4.
Time frame: Change from 3 month follow-up data of health promoting behavior at 1-year
Health-Promoting Lifestyle Profile II questionnaire. Higher score indicate greater health promotion. Minimum score 1 Maximum score 4.
Time frame: Change from 3 month follow-up data of telomerase activity at 1-year
Assessed via peripheral blood mononuclear cells
Time frame: Change from 3 month follow-up data of subjective pain at 1-year
Assessed via the Brief Pain Inventory - Short Form. Measures pain intensity from 0 to 10, 10 being pain as bad as you can imagine. Also measures the extent to which pain interferes with daily functioning (0 - 10 possible, with 10 indicating completely interferes).
Ohio University
Other
Impact of Lifestyle Changes Via the Complete Health Improvement Program on Telomerase Activity and Telomere Length in Patients With Chronic Pain
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07145788
Agnosia, Chronic Pain
Stuttgart, Auerbachstraße 112, Germany
View Trial DetailsNCT07426497
Chronic Pain, Coccydynia
Istanbul, Sisli, Turkey (Türkiye)
View Trial DetailsNCT06931158
Chronic Low-back Pain, Chronic Pain
Providence, Rhode Island, United States
View Trial DetailsNCT06842381
Chronic Pain, Neurologic Manifestations
Almería, Almeria, Spain
View Trial Details